Cellectis SA (CLLS)
3.40
-0.16
(-4.36%)
USD |
NASDAQ |
Aug 28, 16:00
3.43
+0.03
(+0.88%)
After-Hours: 20:00
Cellectis Cash from Investing (Quarterly) : 18.75M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 18.75M |
| March 31, 2026 | -6.187M |
| December 31, 2025 | 22.57M |
| September 30, 2025 | -3.266M |
| June 30, 2025 | -53.11M |
| March 31, 2025 | 4.223M |
| December 31, 2024 | -16.66M |
| September 30, 2024 | 22.33M |
| June 30, 2024 | -106.43M |
| March 31, 2024 | -2.051M |
| December 31, 2023 | -13.65M |
| September 30, 2023 | -0.30M |
| June 30, 2023 | -1.790M |
| March 31, 2023 | 0.23M |
| December 31, 2022 | -0.163M |
| September 30, 2022 | -0.0651M |
| June 30, 2022 | -1.548M |
| March 31, 2022 | -0.9795M |
| December 31, 2021 | -0.204M |
| September 30, 2021 | -2.458M |
| June 30, 2021 | 9.634M |
| Date | Value |
|---|---|
| March 31, 2021 | 0.307M |
| December 31, 2020 | -2.738M |
| September 30, 2020 | 2.278M |
| June 30, 2020 | -5.33M |
| March 31, 2020 | -48.55M |
| December 31, 2019 | -2.533M |
| September 30, 2019 | -25.79M |
| June 30, 2019 | -3.089M |
| March 31, 2019 | -4.456M |
| December 31, 2018 | -2.057M |
| September 30, 2018 | 18.38M |
| June 30, 2018 | 19.85M |
| March 31, 2018 | -0.547M |
| December 31, 2017 | -0.5156M |
| September 30, 2017 | 6.135M |
| June 30, 2017 | -0.8347M |
| March 31, 2017 | -3.000M |
| December 31, 2016 | 58.86M |
| September 30, 2016 | -3.041M |
| June 30, 2016 | -6.444M |
| March 31, 2016 | -102.49M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| DBV Technologies SA | -0.5998M |
| Akari Therapeutics Plc | 0.00 |
| EDAP TMS SA | -1.262M |
| Autolus Therapeutics Plc | 68.03M |
| Evaxion AS | -- |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -14.34M |
| Cash from Financing (Quarterly) | -3.157M |
| Free Cash Flow | -45.36M |
| Free Cash Flow Per Share (Quarterly) | -0.145 |
| Free Cash Flow to Equity (Quarterly) | -10.27M |
| Free Cash Flow to Firm (Quarterly) | -12.72M |
| Free Cash Flow Yield | -13.23% |